- Trials with a EudraCT protocol (55)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
55 result(s) found for: Alternative medicine.
Displaying page 1 of 3.
EudraCT Number: 2011-003652-39 | Sponsor Protocol Number: 30689 | Start Date*: 2012-09-17 | |||||||||||
Sponsor Name:Karen Schow Jensen | |||||||||||||
Full Title: Exercise induced bronchoconstriction in children – a single dose of montelukast as alternative to regular daily doses. | |||||||||||||
Medical condition: Exercise induced asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000898-23 | Sponsor Protocol Number: 2019/KEP/218 | Start Date*: 2019-08-01 | |||||||||||
Sponsor Name:London School of Hygiene and Tropical Medicine | |||||||||||||
Full Title: Pharmacokinetics of intramuscular tranexamic acid in trauma patients: a clinical trial | |||||||||||||
Medical condition: Traumatic haemorrhage | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001385-16 | Sponsor Protocol Number: BACTstudy | Start Date*: 2019-11-22 |
Sponsor Name:Clinic for Medicine and rehabilitation, Nord-Trondelag Trust (HNT) | ||
Full Title: Botulinum toxin A in frequent and chronic tension-type headache. A double blind, randomized, placebo-controlled cross-over trial | ||
Medical condition: Frequent and chronic tension-type headache | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004545-91 | Sponsor Protocol Number: 59874 | Start Date*: 2017-04-13 |
Sponsor Name:VU University Medical Center, department of reproductive Medicine | ||
Full Title: Continuous use of Oral contraceptives as an alternative for long term Pituitary down-regulation with GnRH agonist prior to IVF/ICSI in Endometriosis patients: a randomised controlled trial (COPIE t... | ||
Medical condition: The research population consists of women with surgically confirmed endometriosis ASRM stage III or IV or endometrioma on transvaginal ultrasound or MRI, scheduled for an IVF/ICSI treatment. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000801-21 | Sponsor Protocol Number: 20130218 | Start Date*: 2014-08-26 |
Sponsor Name:Academic Medical Center | ||
Full Title: Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: alternative versus standard stimulation protocols; the STIM-trial | ||
Medical condition: Ovarian stimulation in women with breast cancer prior to chemotherapy | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002529-48 | Sponsor Protocol Number: WADA2018vil | Start Date*: 2018-09-12 | |||||||||||
Sponsor Name:Center for Aktiv Sundhed, Rigshospitalet | |||||||||||||
Full Title: Urine concentrations of vilanterol after inhaled administration of vilanterol/fluticasone furoate: Defining a urine threshold and decision limit for vilanterol in doping control analysis | |||||||||||||
Medical condition: Pharmacokinetics of vilanterol in relation to doping analysis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003729-27 | Sponsor Protocol Number: 0.8 | Start Date*: 2013-11-15 |
Sponsor Name:Queen Mary University of London | ||
Full Title: Telaprevir in patients with genotype 3 HCV : pilot clinical study to evaluate efficacy and predictability of therapy in patients who have failed to respond to pegylated interferon and ribavirin | ||
Medical condition: Genotype 3 HCV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005934-11 | Sponsor Protocol Number: RNLICCCWF1 | Start Date*: 2006-07-11 |
Sponsor Name:Cornwall College Camborne [...] | ||
Full Title: Investigating the possible Therapeutic Effects of the Homoeopathic Remedy Apis Mellifica on Weaver Fish Stings using a Double Blind Randomised Control Trial. | ||
Medical condition: Our medical condition is classified as T63.5 according to the World Health organisation (WHO) International classification of disease. this will be an immunological response to the venom contained ... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-003951-54 | Sponsor Protocol Number: MWD08 | Start Date*: 2010-01-05 | |||||||||||
Sponsor Name:Charité University Medicine Berlin | |||||||||||||
Full Title: Intraveneous induction theraphy followed by oral theraphy against exclusive oral theraphy: randomized trial for the treatment of Whipple's disease | |||||||||||||
Medical condition: ICD 10 K90.8 Sonstige intestinale Malabsorption - Whipple disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000612-17 | Sponsor Protocol Number: HyperplasiLNG | Start Date*: Information not available in EudraCT |
Sponsor Name:University Hospital of North Norway | ||
Full Title: Significance of intrauterine progestogen therapy in endometrial proliferative conditions | ||
Medical condition: Endometrial cancer has presently become the most frequent gynaecologic malinancy in the Western World and the incidence is still increasing. In Norway a 50% increase in occurence has been observed ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005187-63 | Sponsor Protocol Number: FM101-CTP2-001 | Start Date*: 2021-04-14 | ||||||||||||||||
Sponsor Name:Future Medicine Co., Ltd. | ||||||||||||||||||
Full Title: A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH) | ||||||||||||||||||
Medical condition: Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001824-36 | Sponsor Protocol Number: 201201 | Start Date*: 2012-07-12 | ||||||||||||||||
Sponsor Name:Medical University of Vienna, Department of Medicine III, Division of Nephrology und Dialysis | ||||||||||||||||||
Full Title: ORAL SODIUM BICARBONATE SUPPLEMENTATION IN PATIENTS WITH CHRONIC METABOLIC ACIDOSIS AND CHRONIC KIDNEY DISEASE | ||||||||||||||||||
Medical condition: Patients classified to have chronic kidney disease of stage 3 and 4 and chronic metabolic acidosis (venous serum HCO3- of <21mml/L on 2 separate measurements at least 1 day apart) should be include... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000156-38 | Sponsor Protocol Number: 20230123SE | Start Date*: 2023-05-04 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Semmelweis University, Department of Internal Medicine and Oncology | ||||||||||||||||||||||||||||||||||||||
Full Title: Value-based health economic comparative study of subcutaneous and intravenous trastuzumab-pertuzumab for HER-2 positive metastatic breast cancer based on patient reported outcomes. | ||||||||||||||||||||||||||||||||||||||
Medical condition: HER-2 positive advanced breast cancer, locally unresectable or metastatic breast cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: HU (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004810-16 | Sponsor Protocol Number: TPU-TAS-120-101 | Start Date*: 2014-04-10 | |||||||||||
Sponsor Name:Taiho Oncology Inc | |||||||||||||
Full Title: PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS | |||||||||||||
Medical condition: Advanced solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) NL (Completed) PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020841-29 | Sponsor Protocol Number: ADAPT | Start Date*: 2011-07-07 | ||||||||||||||||
Sponsor Name:King`s College London [...] | ||||||||||||||||||
Full Title: The role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema | ||||||||||||||||||
Medical condition: Severe eczema in children | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023880-17 | Sponsor Protocol Number: RR10/9589 | Start Date*: 2011-03-31 | |||||||||||
Sponsor Name:University of Leeds | |||||||||||||
Full Title: SWITCH: Randomised-controlled trial of switching to alternative tumour-necrosis factor (TNF)-blocking drugs or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initia... | |||||||||||||
Medical condition: Rheumatoid arthritis in patients who have failed to respond to an initial TNF-blocking drug | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001621-29 | Sponsor Protocol Number: 80804002 | Start Date*: 2009-05-05 |
Sponsor Name:Faculty of Medicine Carl Gustav Carus, University of Technology, Dresden | ||
Full Title: Pre-POINT (Primary Oral INsulin Trial) study A dose finding safety and immune efficacy study for primary mucosal insulin therapy in islet autoantibody negative children at high genetic risk for ty... | ||
Medical condition: pre-type 1 diabetes (islet autoimmunity in non-diabetic relatives of subjects with type 1 diabetes) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000358-13 | Sponsor Protocol Number: A3921187 | Start Date*: 2014-12-04 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3b/4 RANDOMIZED DOUBLE BLIND STUDY OF 5 MG OF TOFACITINIB WITH AND WITHOUT METHOTREXATE IN COMPARISON TO ADALIMUMAB WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATO... | |||||||||||||
Medical condition: Moderately to severely active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) EE (Completed) LT (Completed) LV (Completed) GB (Completed) ES (Completed) PL (Completed) BG (Completed) RO (Completed) DE (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001520-37 | Sponsor Protocol Number: KETECT | Start Date*: 2014-02-14 | |||||||||||||||||||||||||||||||
Sponsor Name:Skåne University Hospital, Malmö | |||||||||||||||||||||||||||||||||
Full Title: Ketamine as an alternative to electroconvulsive therapy for treatment of major depressive disorder | |||||||||||||||||||||||||||||||||
Medical condition: Major depression disorder | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003385-84 | Sponsor Protocol Number: GO40782(RXDX-101-02) | Start Date*: 2016-03-15 | ||||||||||||||||
Sponsor Name:F. Hoffman-La Roche Ltf | ||||||||||||||||||
Full Title: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRA... | ||||||||||||||||||
Medical condition: Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
